ovarian cancer: a new drug (alnodesertib) with chemo helped 34 of 100 patients live 6 months without their cancer getting worse. chemo alone? 23 of 100. small, early trial, but worth watching.
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary
Artios Pharma announced positive results from a Phase 2a clinical trial for alnodesertib, a new DNA Damage Response (DDR) medicine, in combination with gemcitabine for patients with platinum-resistant
firstwordpharma.com
March 4, 2026 at 8:01 AM
ovarian cancer: a new drug (alnodesertib) with chemo helped 34 of 100 patients live 6 months without their cancer getting worse. chemo alone? 23 of 100. small, early trial, but worth watching.
#ArtiosPharma #ovariancancer #PlatinumResistantOvarianCancer #oncology #GynaecologicalOncology #ovariancancermonth #Alnodesertib #Gemcitabine #biopharma #DDRmedicines #highgradeserousovariancarcinoma #HGSOC #ATRinhibitor #platinumresistantHGSOC #DDRpathways #DNAreplicationstress
zurl.co/XtxxD
zurl.co/XtxxD
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer - Artios Pharma
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancer Study p...
www.artios.com
March 4, 2026 at 12:28 PM
The funds will accelerate clinical programmes in indications of high unmet need. sofinnovapartners.com/news/artios-...
Artios announces oversubscribed $115 million Series D financing to accelerate clinical programs in indications of high unmet need — Sofinnova Partners
Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in for Artios’ alnodesertib
sofinnovapartners.com
November 24, 2025 at 12:42 PM
The funds will accelerate clinical programmes in indications of high unmet need. sofinnovapartners.com/news/artios-...
The company is pioneering therapies targeting the DNA damage response (DDR) field, including its ATR inhibitor alnodesertib and Polθ inhibitor ART6043, with planned Phase 2 expansion in pancreatic, colorectal and breast cancers.
November 24, 2025 at 12:42 PM
The company is pioneering therapies targeting the DNA damage response (DDR) field, including its ATR inhibitor alnodesertib and Polθ inhibitor ART6043, with planned Phase 2 expansion in pancreatic, colorectal and breast cancers.
Alnodesertib, inh selectivo de proteín quinasa relac c/ataxia telangiectasia y Rad3, + gemcitabina, mejora supervivencia libre de progresión y reduce riesgo de progresión o muerte en pac c/CA ovario seroso de alto grado resistente a platino firstwordpharma.com/story/7123373
firstwordpharma.com
March 5, 2026 at 6:10 AM
Alnodesertib, inh selectivo de proteín quinasa relac c/ataxia telangiectasia y Rad3, + gemcitabina, mejora supervivencia libre de progresión y reduce riesgo de progresión o muerte en pac c/CA ovario seroso de alto grado resistente a platino firstwordpharma.com/story/7123373